Long-term effectiveness of acetazolamide on permanent weakness in hyperkalemic periodic paralysis.

Abstract

Acetazolamide is commonly used as an empirical treatment for inherited periodic paralyses although some patients may develop deleterious effects. We report a 65 year-old man with hyperkalemic periodic paralysis and late-onset permanent weakness in association with the common T704M mutation in α-subunit, skeletal muscle voltage-gated sodium channel gene. He rapidly recovered from weakness after acetazolamide treatment. Magnetic resonance imaging of thighs comparing pre- and post-treatment revealed a significant increase in muscle bulk. The patient has been without any type of weakness for over 6 years. This data show the remarkable benefit of acetazolamide on permanent weakness of hyperkalemic periodic paralysis in association with the T704M mutation.

• Authors: Charungthai Dejthevaporn, Chutima Papsing, Bunyong Phakdeekitcharoen, Suphaneewan Jaovisidha, Suchart Phudhichareonrat, Rawiphan Witoonpanich, Teeratorn Pulkes
• Journal: Neuromuscular disorders : NMD (Neuromuscul Disord) Vol. 23 Issue 5 Pg. 445-9 (May 2013) ISSN: 1873-2364 [Electronic] England
• PMID: 23473731 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Elsevier B.V. All rights reserved.

Chemical References

• Acetazolamide

Topics

• Acetazolamide (therapeutic use)
• Aged
• Humans
• Male
• Muscle Weakness (drug therapy)
• Mutation (genetics)
• Paralysis, Hyperkalemic Periodic (diagnosis, drug therapy, genetics, pathology)
• Time
• Treatment Outcome